Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Biocardia Inc
BCDACurrent price
2.99 USD
+0.09 USD (+3.10%)
Last closed
2.95 USD
Company
www.biocardia.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
5 348 744 USD
Yield for 12 month
+232.96 %
1Y
3Y
5Y
10Y
15Y
BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California. Address: 320 Soquel Way, Sunnyvale, CA, United States, 94085
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
60 USDP/E ratio
–Dividend Yield
–Current Year
+477 000 USD
Last Year
+1 352 000 USD
Current Quarter
+55 000 USD
Last Quarter
+13 000 USD
Current Year
+66 000 USD
Last Year
-10 549 000 USD
Current Quarter
-51 000 USD
Last Quarter
-92 000 USD
Key Figures BCDA
1 year
3 years
5 years
10 years
EBITDA
-10 328 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-132.67 %
PEG Ratio
–
Return On Equity TTM
-703.62 %
Wall Street Target Price
60 USD
Revenue TTM
468 000 USD
Book Value
-1.27 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-14.1 %
Dividend Yield
–
Gross Profit TTM
-7 482 000 USD
Earnings per share
-7.05 USD
Diluted Eps TTM
-7.05 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics BCDA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BCDA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:15
Payout Ratio
–
Last Split Date
30.05.2024
Dividend Date
06.06.2019
Stock Valuation BCDA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
22.2956
Price Sales TTM
21.8512
Enterprise Value EBITDA
-0.92
Price Book MRQ
10.6661
Financials BCDA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators BCDA
For 52 weeks
2.62 USD
23.25 USD
50 Day MA
3.96 USD
Shares Short Prior Month
77 130
200 Day MA
6.54 USD
Short Ratio
0.14
Shares Short
47 987
Short Percent
3.04 %
BeatStart